EYPT - EyePoint Q1 net loss widens Y/Y; inks license deal with China's Betta for EYP-1901

EyePoint Pharmaceuticals (NASDAQ:EYPT) signed a license agreement with China-based Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan (the Territory). EyePoint said it will retain global ophthalmic rights for EYP-1901 in the rest of the world. The company said EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration (wet AMD), combining a bioerodible formulation of EyePoint's proprietary Durasert delivery technology with vorolanib, a tyrosine kinase inhibitor. The agreement expands the collaboration between EyePoint and Equinox Sciences, an affiliate of Betta Pharmaceuticals. In addition, EyePoint said it has amended a February 2020 license agreement with Equinox, expanding EyePoint’s exclusive rights to develop and commercialize vorolanib, through localized delivery for treating all ophthalmic diseases, including DME, outside of the Territory. Separately, EyePoint reported its Q1 results, where revenue missed analysts' estimates. Total revenues increased +26.92% Y/Y to $9.29M. Net product revenue grew

For further details see:

EyePoint Q1 net loss widens Y/Y; inks license deal with China's Betta for EYP-1901